Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily was used to treat 76 postmenopausal women with advanced breast cancer. There were 4 CR, 17 PR (objective response rate 28%). Highest response was in soft tissue. CNS toxicity was less than with conventional dose AG (drowsiness 7% v. 31%), although the incidence of rash was equivalent. Previous responders to tamoxifen had a higher response (33%) than previous non-responders (9%). The lower toxicity and maintained efficacy suggest that this should be the standard dosage regimen.
D000368:Aged; D000616:Aminoglutethimide / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008593:Menopause; D011379:Prognosis
D000616:Aminoglutethimide; D006854:Hydrocortisone